Literature DB >> 25503144

Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.

Stefano De Luca1, Roberto Passera2, Enrico Bollito3, Matteo Manfredi4, Roberto Mario Scarpa4, Antonino Sottile5, Donato Franco Randone6, Francesco Porpiglia4.   

Abstract

AIM: To determine if prostate cancer gene 3 (PCA3) score, Prostate Health Index (PHI), and percent free prostate-specific antigen (%fPSA) may be used to differentiate prostatitis from prostate cancer (PCa), benign prostatic hyperplasia (BPH) and high-grade prostate intraepithelial neoplasia (HG-PIN) in patients with elevated PSA and negative digital rectal examination (DRE). PATIENTS AND METHODS: in the present prospective study, 274 patients, undergoing PCA3 score, PHI and %fPSA assessments before initial biopsy, were enrolled. Three multivariate logistic regression models were used to test PCA3 score, PHI and %fPSA as risk factors for prostatitis vs. PCa, vs. BPH, and vs. HG-PIN. All the analyses were performed for the whole patient cohort and for the 'gray zone' of PSA (4-10 ng/ml) cohort (188 individuals).
RESULTS: The determinants for prostatitis vs. PCa were PCA3 score, PHI and %fPSA (Odds Ratio [OR]=0.97, 0.96 and 0.94, respectively). Unit increase of PHI was the only risk factor for prostatitis vs. BPH (OR=1.06), and unit increase of PCA3 score for HG-PIN vs. prostatitis (OR=0.98). In the 'gray zone' PSA cohort, the determinants for prostatitis vs. PCa were PCA3 score, PHI and %fPSA (OR=0.96, 0.94 and 0.92, respectively), PCA3 score and PHI for prostatitis vs. BPH (OR=0.96 and 1.08, respectively), and PCA3 score for prostatitis vs. HG-PIN (OR=0.97).
CONCLUSION: The clinical benefit of using PCA3 score and PHI to estimate prostatitis vs. PCa was comparable; even %fPSA had good diagnostic performance, being a faster and cheaper marker. PHI was the only determinant for prostatitis vs. BPH, while PCA3 score for prostatitis vs. HG-PIN. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Prostate Health Index; Prostate cancer; differential diagnosis; percentage free prostate-specific antigen; prostate cancer antigen 3 gene; prostate-specific antigen; prostatitis

Mesh:

Substances:

Year:  2014        PMID: 25503144

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients.

Authors:  Wei Wei; Jiangyong Leng; Hongxiang Shao; Weidong Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis.

Authors:  Sandra Viviana Muñoz Rodríguez; Herney Andrés García-Perdomo
Journal:  Can Urol Assoc J       Date:  2019-11-29       Impact factor: 1.862

3.  Urinary PCA3 a Superior Diagnostic Biomarker for Prostate Cancer among Ghanaian Men.

Authors:  Bismark Opoku Mensah; Linda Ahenkorah Fondjo; W K B A Owiredu; Ben Adusei
Journal:  Dis Markers       Date:  2022-10-07       Impact factor: 3.464

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.